These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 6867995)

  • 1. [Elimination half-life of 3-hydroxyquinidine in man].
    Camsonne R; Moulin MA; Bazin C; Charbonneau P; Drieu L; Pedailles S; Briand A
    Therapie; 1983; 38(1):115-6. PubMed ID: 6867995
    [No Abstract]   [Full Text] [Related]  

  • 2. Elimination kinetic of high polar metabolites pool of quinidine from human serum.
    Camsonne R; Moulin MA; Charbonneau P; Bazin C
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):74-5. PubMed ID: 3988396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accumulation of 3-hydroxyquinidine following chronic quinidine therapy.
    Ackerman BH; Olsen KM; Pappas AA
    DICP; 1991; 25(7-8):867-9. PubMed ID: 1949948
    [No Abstract]   [Full Text] [Related]  

  • 4. Total and unbound concentrations of quinidine and 3-hydroxyquinidine at steady state.
    Wooding-Scott RA; Visco J; Slaughter RL
    Am Heart J; 1987 Feb; 113(2 Pt 1):302-6. PubMed ID: 3812182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of 3-hydroxyquinidine in patients receiving initial intravenous quinidine gluconate for electrophysiology testing of ventricular tachycardia.
    Ackerman BH; Olsen KM; Kennedy EE; Taylor EH; Chen BH; Jordan D; Ackerman DJ
    DICP; 1989 May; 23(5):375-8. PubMed ID: 2728524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine.
    Edwards DJ; Lavoie R; Beckman H; Blevins R; Rubenfire M
    Clin Pharmacol Ther; 1987 Jan; 41(1):68-73. PubMed ID: 3802708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged quinidine half-life with associated toxicity in a patient with hepatic failure.
    Stanek EJ; Simko RJ; DeNofrio D; Pavri BB
    Pharmacotherapy; 1997; 17(3):622-5. PubMed ID: 9165569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence supporting 3(S)-3-hydroxyquinidine-associated cardiotoxicity.
    Bowers LD; Nelson KM; Connor R; Lais CJ; Krauss E
    Ther Drug Monit; 1985; 7(3):308-12. PubMed ID: 4049469
    [No Abstract]   [Full Text] [Related]  

  • 9. [Chronic renal insufficiency. Elevated levels of the active metabolite (3-hydroxyquinidine) of quinidine].
    Camsonne R; Moulin MA; Ryckelynck JP; Mignot P; Albessard F; Perault M; Bigot MC; Richard O
    Nouv Presse Med; 1982 Oct; 11(41):3062-3. PubMed ID: 7145692
    [No Abstract]   [Full Text] [Related]  

  • 10. [Quinidine and enzyme induction. Erroneous interpretation of the plasma levels of 3-hydroxyquinidine and O-demethylquinidine].
    Leroyer R; Jarreau C; Pays M
    Therapie; 1984; 39(1):57-9. PubMed ID: 6463946
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical pharmacology of anti-arrhythmia agents. I. Quinidine, procainamide and disopyramide].
    Witkowska M
    Kardiol Pol; 1981; 24(7):505-17. PubMed ID: 7024612
    [No Abstract]   [Full Text] [Related]  

  • 12. [Estimation of residual rate and apparent half-life time of drugs using the method of acute mortality of animals].
    He MS; Zhan LF; Guo JY; Zhang YZ
    Zhongguo Yao Li Xue Bao; 1985 Sep; 6(3):213-6. PubMed ID: 2943131
    [No Abstract]   [Full Text] [Related]  

  • 13. Greater quinidine-induced QTc interval prolongation in women.
    Benton RE; Sale M; Flockhart DA; Woosley RL
    Clin Pharmacol Ther; 2000 Apr; 67(4):413-8. PubMed ID: 10801251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid elimination of quinidine in pediatric patients.
    Szefler SJ; Pieroni DR; Gingell RL; Shen DD
    Pediatrics; 1982 Sep; 70(3):370-5. PubMed ID: 7110810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenytoin-induced changes in quinidine and 3-hydroxyquinidine pharmacokinetics in conscious dogs.
    Jaillon P; Kates RE
    J Pharmacol Exp Ther; 1980 Apr; 213(1):33-7. PubMed ID: 7359368
    [No Abstract]   [Full Text] [Related]  

  • 16. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
    Knapp W; Lechleitner P
    Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the interaction of 3S-hydroxy-10,11-dihydroquinidine on the pharmacokinetics and pharmacodynamics of warfarin.
    Trenk D; Möhrke W; Warth L; Jähnchen E
    Arzneimittelforschung; 1993 Aug; 43(8):836-41. PubMed ID: 8216438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced clearance of quinidine in elderly humans.
    Ochs HR; Greenblatt DJ; Woo E; Franke K; Smith TW
    Verh Dtsch Ges Kreislaufforsch; 1977; 43():426. PubMed ID: 613678
    [No Abstract]   [Full Text] [Related]  

  • 19. Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading.
    Fromm MF; Darbar D; Dell'Orto S; Roden DM
    J Pharmacol Exp Ther; 1999 Jul; 290(1):253-8. PubMed ID: 10381784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of quinine and its metabolites in pregnant Sudanese women with uncomplicated Plasmodium falciparum malaria.
    Abdelrahim II; Adam I; Elghazali G; Gustafsson LL; Elbashir MI; Mirghani RA
    J Clin Pharm Ther; 2007 Feb; 32(1):15-9. PubMed ID: 17286785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.